Ireland has evolved into one of the world’s most critical locations for the global Pharmaceutical Industry.

Today, with more than 90 FDA-approved facilities, 50,000 people employed in the sector, and more than 125 billion euro in annual pharmaceutical exports, the country combines stability, world-class talent and an integrated global supply chain which ensures the uninterrupted supply of life-saving medicines for patients around the world. Ireland remains a stable and trusted partner for the global pharmaceutical industry.

A 60-year foundation of reliability and regulatory excellence

Ireland’s leadership position in the global pharmaceutical industry is no accident. In the late 1960s, Ireland made a strategic decision to open itself to global industry. Established companies chose Ireland for small-molecule manufacturing because of a location with strong access to the European market, a financially attractive and efficient operating base and a stable policy environment, factors which continue to underpin Ireland’s position as a global Biopharmaceutical manufacturing location of choice today. These sites, along with many others and labelling and packaging manufacturers such as ourselves, continue to thrive in small molecule manufacturing. In Ireland today, there are now 50 sites manufacturing Active Pharmaceutical Ingredients and drug products and support services being exported around the world.

 FDA inspections in Ireland routinely reaffirm that confidence. In an industry where patient safety comes first and compliance can never be compromised, Ireland has become a trusted, dependable manufacturing base.